Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alector Inc (NQ: ALEC )

6.580 -0.110 (-1.64%)
Streaming Delayed Price Updated: 10:37 AM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alector Inc

< Previous 1 2 3 4 Next >
Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023
Via Benzinga
Analyst Expectations for Alector's Future
Via Benzinga
Expert Ratings for Alector
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2023
Via Benzinga
Alibaba, Standard Lithium, Anterix And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Nasdaq Composite gaining 100 points on Friday. Here are some big stocks recording gains in today’s session. Lifezone Metals Limited (NYSE: LZM) surged 27.4% to... 
Via Benzinga
Topics Stocks
Exposures US Equities
Preview: Alector's Earnings
Via Benzinga
Analyst Expectations for Alector's Future
Via Benzinga
How The Same Treatments May Work For Multiple Neurodegenerative Diseases
Extensive research on NDDs has uncovered a different treatment pathway that's enabling some biotechnology firms to target more than one NDD with the same drug candidate. 
Via Talk Markets
Alector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimer’s Disease
Data readout expected in Q4 2024 
From Alector, Inc.
Via GlobeNewswire
Alector to Participate in Upcoming Healthcare Conferences
From Alector, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Alector Reduces Workforce To Support Recent Reprioritizing Plans
Via Benzinga
Analyst Expectations for Alector's Future
Via Benzinga
Why ResMed Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Missfresh Limited (NASDAQ: MF) jumped 168% to $1.38 after the company announced entry of share purchase agreements for financing and business acquisition. 
Via Benzinga
Atlassian, Universal Display, Booking, Dropbox And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Alector Reports Second Quarter 2023 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Alector to Host Mid-Year Earnings Conference Call
Call Scheduled for Thursday, August 3, 2023, at 4:30 p.m. ET/1:30 p.m. PT 
From Alector, Inc.
Via GlobeNewswire
7 Stocks That AI Says Will Make You a Millionaire by 2025
These seven millionaire-maker stocks are changing hands at deeply undervalued levels. As their growth re-accelerates, so will your portfolio. 
Via InvestorPlace
Alector to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
From Alector, Inc.
Via GlobeNewswire
Alector Reports First Quarter 2023 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Alector to Participate in the BofA Securities 2023 Healthcare Conference
From Alector, Inc.
Via GlobeNewswire
Alector to Participate in Upcoming Healthcare Conferences
From Alector, Inc.
Via GlobeNewswire
Alector Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From Alector, Inc.
Via GlobeNewswire
Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Alector, Inc.
Via GlobeNewswire
Alector Presents Results from First-in-Human Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases
From Alector, Inc.
Via GlobeNewswire
Alector Reports Third Quarter 2022 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Why Merrimack Pharmaceuticals Shares Jumped Around 213%; Here Are 114 Biggest Movers From Yesterday
Gainers 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.